RxDoctor Payments Data

Ryan Brogan, NP

Family · Plymouth, MANPI 1518476498

Payments from drug & device makers

$5,215in general payments, 2019–2025

Across 242 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$533
  • Novartis$532
  • Amgen$498
  • Johnson & Johnson$470
  • Novo Nordisk$467
  • Pfizer$457
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,215100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,215 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$75,781
Medicare patients
377
Services billed
1,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$118,586
EntrestoSacubitril/Valsartan39$57,253
XareltoRivaroxaban29$35,998
JardianceEmpagliflozin18$30,220
Repatha SyringeEvolocumab19$29,850
OzempicSemaglutide13$12,579
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,408
Nifedipine ErNifedipine68$2,926
Adderall XrDextroamphetamine/Amphetamine11$2,684
Metoprolol Succinate133$2,483
Atorvastatin Calcium162$2,183
Verapamil SrVerapamil Hcl12$1,972
Flecainide Acetate31$1,795
Lisinopril198$1,460
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$1,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$457$118,58679 claims
NovartisEntresto$532$57,25339 claims
Johnson & JohnsonXarelto$470$35,99829 claims
Boehringer IngelheimJardiance$533$30,22018 claims
Novo NordiskOzempic$467$12,57913 claims
GSKTrelegy Ellipta$60$12,40814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.

Other family in Plymouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →